Table 3. Cox regression analyses for time to CRPC in cohort 2 (104 metastatic PCa patients).

	Univariate analysis		Multivariate analysis
Covariates	HR (95% CI)	p Value	HR (95% CI)	p Value
Age at diagnosis (ref: <70 years)	1.003 (0.979–1.027)	0.828	1.003 (0.980–1.027)	0.782
PSA at diagnosis (ref: <122.5 ng/mL)	1.000 (1.000–1.000)	0.867	1.000 (1.000–1.000)	0.930
Gleason score at diagnosis (ref: ≤6)
7	1.071 (0.506–2.266)	0.858	1.428 (0.646–3.156)	0.378
≥8	1.244 (0.612–2.531)	0.547	1.248 (0.599–2.602)	0.554
M stage at diagnosis (ref: M1a)
M1b	1.288 (0.471–3.525)	0.622	1.085 (0.389–3.023)	0.876
M1c	1.451 (0.445–4.730)	0.537	0.999 (0.243–4.101)	0.999
Nadir PSA (ref: <0.7 ng/mL)	1.011 (1.001–1.020)	0.023	1.012 (1.002–1.022)	0.019
Time to nadir PSA (ref: <9.0 month)	1.004 (0.990–1.017)	0.594	1.012 (.997–1.027)	0.114
PSAHL (ref: <0.9 month)	1.023 (1.001–1.046)	0.041	1.024 (.995–1.054)	0.107
AR-V7 expression (ref: negative)	2.312 (1.418–3.770	0.001	2.627 (1.480–4.663)	0.001